GoodRx Holdings, Inc. (GDRX)
Health Care · Digital Health Platforms · NASDAQ
GoodRx is a leading digital healthcare platform helping consumers navigate the complexities of prescription drug pricing and access affordable care.
What GoodRx Holdings, Inc. does
GoodRx Holdings operates a digital healthcare platform that provides consumers with tools to compare prescription drug prices and find discounts. The company connects consumers with pharmacy benefit managers (PBMs) to offer savings at pharmacies and also provides digital healthcare services for online provider consultations and treatment.
Themes: digital health, prescription price transparency, telehealth, pharmacy services
Fundamentals
- Price$3.52 as of 2026-10-20 close
- Market cap$1.2B as of 2026-07-28 (share count; price 2026-10-20)
- 1-year return-11.6% 2025-10-20 close $3.98 → 2026-10-20 close $3.52
- P/E58.67 as of 2026-10-20
- Net margin+3.8% FY2025, SEC XBRL
- ROE+4.9% FY2025, SEC XBRL
- ROIC+5.8% NOPAT / (debt + equity - cash), average capital — 10-K FY2025 (year ended 2025-12-31)
- Debt / equity0.75 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+0.6% FY2025, SEC XBRL
- Revenue CAGR (3y)+1.3% SEC XBRL
- Beta1.22 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How GDRX compares in its sector
- price-to-earnings ratiotop 25% 181 covered Health Care peers, as of 2026-10-20
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which GDRX reported a dividend payment is FY2018, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2018 ratio would not describe GDRX today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2018) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $200M | $24M | $9M | $0.02 | $81M† | $362000† |
| Q1 FY2026 2026-03-31 | $194M | $14M | $1M | $0.00 | $12M | $1M |
| Q4 FY2025 2025-12-31 | $195M† | $23M† | $5M† | $0.02† | $33M† | $1M† |
| Q3 FY2025 2025-09-30 | $196M | $15M | $1M | $0.00 | $76M† | $2M† |
| Q2 FY2025 2025-06-30 | $203M | $27M | $13M | $0.04 | $50M† | $390000† |
| Q1 FY2025 2025-03-31 | $203M | $23M | $11M | $0.03 | $9M | $142000 |
| Q4 FY2024 2024-12-31 | $199M† | $18M† | $7M† | $0.02† | $45M† | $162000† |
| Q3 FY2024 2024-09-30 | $195M | $20M | $4M | $0.01 | $87M† | $403000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$296M
- Total debt$487M borrowings only; leases excluded
- Net debt$190M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How GoodRx Holdings, Inc. looks technically
GoodRx Holdings, Inc. (GDRX) is trading 25.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 66 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-09-14, pushing above its recent trading range. It is 18.7% below its highest point of the past year. Trading volume is running unusually high — about 2.8× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 25.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +25.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.45 | $3.45 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.80 | $2.80 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 3.2. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 66 trading days ago — a "golden cross", a bullish long-term signal | 66 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 19.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 56.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($3.20 to $3.55) — its "stochastic" reading is 91 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 91.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.33 | $4.33 |
|---|---|---|
| From the 52-week high | it is 18.7% below its 52-week high (its highest price of the past year) | -18.7% |
| Above the 52-week low | it is 98.9% above its 52-week low (its lowest price of the past year) | +98.9% |
| Below the 52-week high | it is 18.7% below its highest point of the past year | 18.7% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-09-14, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 50 trading days ago | 50 sessions |
| All-time high | its highest closing price on record is $51.78 (set on 2021-02-22) | $51.78 |
| Given back of the 52-week move | over the past year its closes ranged ($1.87 to $4.16), and it has recovered well over two thirds of its fall from last year’s high — 72% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.29 to $3.36. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 72.0% |
| From the all-time high | it is 93.2% below its all-time high | -93.2% |
| Nearest price level | it is trading 4.6% below a resistance level at $3.68 — a price it turned at twice since 2025-05-07, most recently on 2025-05-23. Since 2024-10-21 it has 9 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +4.6% |
| All-time low | its lowest closing price on record is $1.77 (set on 2026-03-02) | $1.77 |
| Above the all-time low | it is 98.9% above its all-time low | +98.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 82% of it) | 18th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1204 between its high and its low — about 3.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1204 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.19 and $3.52 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.19 – $3.36 – $3.52 |
| Typical daily range (% of price) | its price moves about 3.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.4% |
| Stretch from the 200-day average | it is trading 6.0 daily ranges above its 200-day average price (25.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.8× its 30-day average, a sign of heightened interest | 2.77× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.3% |
|---|---|---|
| Open gap | it gapped 2.6% above the previous close 55 sessions ago and has not traded back through the level it left behind at 3.07 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.6% |
| Gap filled | a 4.6% gap up opened on 2026-08-06 has been "filled" 52 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 52 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +4.76% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 3.2 percentage points (the stock gained 4.1% while the market gained 1.0%) | +3.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 8.5 percentage points (the stock gained 12.1% while the market gained 3.6%) | +8.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 40.0 percentage points (the stock gained 48.5% while the market gained 8.5%) | +40.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 26.1 percentage points (the stock lost 11.6% while the market gained 14.6%) | -26.1% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.2% of the share price. | +0.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 33% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $2.66 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | +32.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $3.51 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | +0.3% |
Falling wedge, bullish — broke out · entry $3.35 · 49 sessions in
Price levels it has turned at before
GDRX last closed at $3.52 on 2026-10-20. Since 2024-10-21 it has turned at 9 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.68 | Resistance | 4.6% above the last close | turned there twice · 2025-05-07 to 2025-05-23 |
| $3.30 | Support | 6.3% below the last close | turned there three times · 2025-08-07 to 2026-09-18 |
| $3.21 | Support | 8.8% below the last close | turned there twice · 2026-07-20 to 2026-10-02 |
| $3.85 | Resistance | 9.5% above the last close | turned there three times · 2025-04-07 to 2026-08-11 |
| $3.13 | Support | 11.2% below the last close | turned there twice · 2026-06-02 to 2026-07-01 |
| $4.08 | Resistance | 16.1% above the last close | turned there three times · 2024-11-15 to 2025-10-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $3.20.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 8 trading days, since 2026-10-09.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Unusually heavy trading volume · Broke out to a new 20-day high · Broke out to a new 20-day high on heavy volume · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.64 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$3.95 range $2.65 – $5.00; median $4.00
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GDRX
- Consensus EPS estimate$0.07787 next reporting period, as of 2026-10-16
- Estimate change, 30 days-$0.00059 from $0.07846, on 2026-09-11, 35-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on a limited number of pharmacy benefit managers for a significant portion of revenue.","Regulatory and legal environment governing healthcare, pharmacies, and drug pricing.","Potential impacts of market competition and changes in consumer prescription purchasing behavior."]
What changed in the latest 10-Q
AI-assisted comparison of GDRX's 10-Q filed 2026-08-05 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Added:
- In the newer filing (2026-08-05), the 'subscribers' glossary definition includes 'GoodRx Companion which launched its monthly and annual plans in May and July 2026, respectively' as one of the subscription offerings.
- Removed:
- In the older filing (2026-05-06), the 'Monthly Active Consumers' glossary definition included the sentence 'Effective January 1, 2025, Monthly Active Consumers from acquired companies are included beginning from the acquisition date.' This sentence does not appear in the newer filing's 'Monthly Active Consumers' definition.
- Reworded:
- In the newer filing (2026-08-05), the 'Monthly Active Consumers' glossary definition ends with 'Monthly Active Consumers from acquired companies are included beginning from the acquisition date' without stating the effective date, whereas the older filing (2026-05-06) stated 'Effective January 1, 2025, Monthly Active Consumers from acquired companies are included beginning from the acquisition date.'
- Notes:
- The provided newer filing text ends mid-sentence in the Overview section ('...we are building the leading consumer-focused digital healthcare platform in the'), and the older filing text ends mid-sentence in the Overview section ('...For example, in the first quarter of 2026, we announce'), so changes after those truncation points cannot be assessed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 14 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 14 sells ($10M) — 1 selling insider
- Last 180 days · read to 2026-10-160 buys · 14 sells ($10M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-26. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GDRX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding GDRX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 6,110,557
- Reported value $17,598,400
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 1 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about GDRX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
GDRX had 4,155,510 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for GDRX because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 4,155,510
- Prior settlement (shares) 4,725,939
- Reported change -12.07%
- Days to cover (reported) 5.37
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amazon Pharmacy (AMZN)
- CVS Health (CVS)
- Walgreens Boots Alliance (WBA)
- SingleCare
- Blink Health
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GDRX vs…
GoodRx Holdings, Inc. is found in…
Frequently asked questions
What does GoodRx Holdings, Inc. (GDRX) do?
GoodRx Holdings operates a digital healthcare platform that provides consumers with tools to compare prescription drug prices and find discounts. The company connects consumers with pharmacy benefit managers (PBMs) to offer savings at pharmacies and also provides digital healthcare services for online provider consultations and treatment.
What sector is GoodRx Holdings, Inc. (GDRX) in?
GoodRx Holdings, Inc. (GDRX) is classified in the Health Care sector. Its industry is Digital Health Platforms. It trades on NASDAQ.
Who are GoodRx Holdings, Inc.'s (GDRX) competitors?
Notable peers of GoodRx Holdings, Inc. (GDRX) include Amazon Pharmacy, CVS Health, Walgreens Boots Alliance, SingleCare and Blink Health. This peer set is informational only — not financial advice.
Is GoodRx Holdings, Inc. (GDRX) overbought or oversold right now?
GoodRx Holdings, Inc. (GDRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GDRX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.